[go: up one dir, main page]

WO2021116503A3 - Composés deutérés - Google Patents

Composés deutérés Download PDF

Info

Publication number
WO2021116503A3
WO2021116503A3 PCT/EP2021/060750 EP2021060750W WO2021116503A3 WO 2021116503 A3 WO2021116503 A3 WO 2021116503A3 EP 2021060750 W EP2021060750 W EP 2021060750W WO 2021116503 A3 WO2021116503 A3 WO 2021116503A3
Authority
WO
WIPO (PCT)
Prior art keywords
deuterated
dimethyltryptamine
compounds
compound
therapeutic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/060750
Other languages
English (en)
Other versions
WO2021116503A8 (fr
WO2021116503A2 (fr
Inventor
Peter RANDS
Tiffanie BENWAY
Zelah JOEL
Marie LAYZELL
Ellen James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Small Pharma Ltd
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/890,664 external-priority patent/US11771681B2/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority to NZ794833A priority Critical patent/NZ794833A/en
Priority to JP2022574099A priority patent/JP7288154B2/ja
Priority to PL21720509.5T priority patent/PL3902541T3/pl
Priority to CA3179161A priority patent/CA3179161C/fr
Priority to AU2021204158A priority patent/AU2021204158B2/en
Priority to ES21720509T priority patent/ES2928395T3/es
Priority to MX2022014900A priority patent/MX2022014900A/es
Priority to IL298541A priority patent/IL298541B2/en
Priority to KR1020227045704A priority patent/KR102589605B1/ko
Priority to CN202180046463.XA priority patent/CN116056763B/zh
Priority to EP21720509.5A priority patent/EP3902541B1/fr
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Priority to IL298542A priority patent/IL298542B2/en
Priority to AU2021284861A priority patent/AU2021284861A1/en
Priority to EP21725377.2A priority patent/EP4149460B8/fr
Priority to EP24215587.7A priority patent/EP4494703A3/fr
Priority to JP2022574098A priority patent/JP7579888B2/ja
Priority to CN202180046533.1A priority patent/CN115996713A/zh
Priority to GB2106881.2A priority patent/GB2595776B/en
Priority to CA3118556A priority patent/CA3118556A1/fr
Priority to US17/320,155 priority patent/US12042564B2/en
Priority to PCT/EP2021/062794 priority patent/WO2021244831A1/fr
Publication of WO2021116503A2 publication Critical patent/WO2021116503A2/fr
Publication of WO2021116503A8 publication Critical patent/WO2021116503A8/fr
Priority to US17/458,167 priority patent/US11471417B2/en
Priority to TW110143066A priority patent/TWI891942B/zh
Priority to EP21815486.2A priority patent/EP4031529B1/fr
Priority to PCT/EP2021/082227 priority patent/WO2022117359A1/fr
Priority to IL303288A priority patent/IL303288A/en
Priority to EP23198784.3A priority patent/EP4275753A3/fr
Priority to CN202180090269.1A priority patent/CN116761599B/zh
Priority to AU2021391581A priority patent/AU2021391581A1/en
Priority to CA3203020A priority patent/CA3203020A1/fr
Priority to JP2023533243A priority patent/JP2023551058A/ja
Priority to US18/252,949 priority patent/US20240016782A1/en
Priority to PCT/EP2021/083755 priority patent/WO2022117640A1/fr
Priority to EP21816489.5A priority patent/EP4255421A1/fr
Priority to US17/680,411 priority patent/US11660289B2/en
Anticipated expiration legal-status Critical
Priority to US18/163,388 priority patent/US12251371B2/en
Publication of WO2021116503A3 publication Critical patent/WO2021116503A3/fr
Priority to US18/748,483 priority patent/US20240342101A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé N,N-diméthyltryptamine deutéré ou une pluralité de composés N,N-diméthyltryptamine deutérés destinés à être utilisés en thérapie, sélectionnés parmi les composés N,N-diméthyltryptamine, les composés α-protio, α-deutéro-N,N- diméthyltryptamine, les composés α,α-dideutéro-N,N-diméthyltryptamine, et des sels pharmaceutiquement acceptables de ces composés, préférablement le composé N,N-diméthyltryptamine deutéré présentant une demi-vie accrue par rapport au composé N,N-diméthyltryptamine non deutéré. En particulier, l'invention concerne un composé de formule I, ou un sel pharmaceutiquement acceptable de celui-ci; (I) le rapport deutérium:protium dans le composé étant supérieur à celui trouvé naturellement dans l'hydrogène; chaque R1 étant sélectionné indépendamment parmi H et D; R2 étant sélectionné parmi CH3 et CD3; R3 étant sélectionné parmi CH3 et CD3; et chaque yH étant sélectionné indépendamment parmi H et D. Des procédés de synthèse de composés de la présente invention, et des procédés d'utilisation de telles compositions dans le traitement de troubles psychiatriques ou neurologiques, tels que le trouble dépressif majeur, sont également fournis.
PCT/EP2021/060750 2020-06-02 2021-04-23 Composés deutérés Ceased WO2021116503A2 (fr)

Priority Applications (37)

Application Number Priority Date Filing Date Title
EP21720509.5A EP3902541B1 (fr) 2020-06-02 2021-04-23 Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés
CN202180046463.XA CN116056763B (zh) 2020-06-02 2021-04-23 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物
KR1020227045704A KR102589605B1 (ko) 2020-06-02 2021-04-23 중수소화 또는 부분 중수소화 n,n-디메틸트립타민 화합물을 포함하는 치료용 조성물
JP2022574099A JP7288154B2 (ja) 2020-06-02 2021-04-23 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物
NZ794833A NZ794833A (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
PL21720509.5T PL3902541T3 (pl) 2020-06-02 2021-04-23 Kompozycje terapeutyczne zawierające deuterowane lub częściowo deuterowane związki n,n-dimetyltryptaminy
CA3179161A CA3179161C (fr) 2020-06-02 2021-04-23 Compositions therapeutiques comprenant des composes de n,n-dimethyl tryptamine deuteree ou partiellement deuteree
AU2021204158A AU2021204158B2 (en) 2020-06-02 2021-04-23 Deuterated compounds
ES21720509T ES2928395T3 (es) 2020-06-02 2021-04-23 Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados
MX2022014900A MX2022014900A (es) 2020-06-02 2021-04-23 Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
IL298541A IL298541B2 (en) 2020-06-02 2021-04-23 1,1-dideuterio-2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine and a medical preparation containing it
CA3118556A CA3118556A1 (fr) 2020-06-02 2021-05-13 Formes de dosages solides therapeutiques
US17/320,155 US12042564B2 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
PCT/EP2021/062794 WO2021244831A1 (fr) 2020-06-02 2021-05-13 Formes galéniques solides thérapeutiques
AU2021284861A AU2021284861A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
CN202180046533.1A CN115996713A (zh) 2020-06-02 2021-05-13 治疗性固体剂型
GB2106881.2A GB2595776B (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
EP21725377.2A EP4149460B8 (fr) 2020-06-02 2021-05-13 Formes galéniques solides thérapeutiques
EP24215587.7A EP4494703A3 (fr) 2020-06-02 2021-05-13 Formes galéniques solides thérapeutiques
JP2022574098A JP7579888B2 (ja) 2020-06-02 2021-05-13 治療用固形製剤
IL298542A IL298542B2 (en) 2020-06-02 2021-05-13 Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts
US17/458,167 US11471417B2 (en) 2020-06-02 2021-08-26 Deuterated N,N-dimethyltryptamine compounds
AU2021391581A AU2021391581A1 (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP21815486.2A EP4031529B1 (fr) 2020-12-01 2021-11-18 Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
CA3203020A CA3203020A1 (fr) 2020-12-01 2021-11-18 Composes de n,n-dimethyltryptamine deuteres ou partiellement deuteres
TW110143066A TWI891942B (zh) 2020-12-01 2021-11-18 氘化化合物
CN202180090269.1A CN116761599B (zh) 2020-12-01 2021-11-18 氘代或部分氘代的n,n-二甲基色胺化合物
JP2023533243A JP2023551058A (ja) 2020-12-01 2021-11-18 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物
PCT/EP2021/082227 WO2022117359A1 (fr) 2020-12-01 2021-11-18 Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
IL303288A IL303288A (en) 2020-12-01 2021-11-18 Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP23198784.3A EP4275753A3 (fr) 2020-12-01 2021-11-18 Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
US18/252,949 US20240016782A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
EP21816489.5A EP4255421A1 (fr) 2020-12-01 2021-12-01 Formulations inhalables
PCT/EP2021/083755 WO2022117640A1 (fr) 2020-12-01 2021-12-01 Formulations inhalables
US17/680,411 US11660289B2 (en) 2020-12-01 2022-02-25 Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US18/163,388 US12251371B2 (en) 2020-12-01 2023-02-02 Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US18/748,483 US20240342101A1 (en) 2020-06-02 2024-06-20 Therapeutic solid dosage forms

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
PCT/EP2020/065244 WO2020245133A1 (fr) 2019-06-03 2020-06-02 Compositions thérapeutiques comprenant des composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
EPPCT/EP2020/065244 2020-06-02
GB2008303.6 2020-06-02
US16/890,664 2020-06-02
GB2018950.2 2020-12-01
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
GB2018955.1 2020-12-01
US17/108,938 2020-12-01
US17/108,679 2020-12-01
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/208,583 2021-03-22
GB2103981.3 2021-03-22
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/458,167 Continuation US11471417B2 (en) 2020-06-02 2021-08-26 Deuterated N,N-dimethyltryptamine compounds

Publications (3)

Publication Number Publication Date
WO2021116503A2 WO2021116503A2 (fr) 2021-06-17
WO2021116503A8 WO2021116503A8 (fr) 2021-08-12
WO2021116503A3 true WO2021116503A3 (fr) 2023-09-28

Family

ID=76329655

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2021/060750 Ceased WO2021116503A2 (fr) 2020-06-02 2021-04-23 Composés deutérés
PCT/EP2021/062794 Ceased WO2021244831A1 (fr) 2020-06-02 2021-05-13 Formes galéniques solides thérapeutiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/062794 Ceased WO2021244831A1 (fr) 2020-06-02 2021-05-13 Formes galéniques solides thérapeutiques

Country Status (8)

Country Link
EP (3) EP3902541B1 (fr)
JP (1) JP7579888B2 (fr)
CN (1) CN115996713A (fr)
AU (1) AU2021284861A1 (fr)
CA (1) CA3118556A1 (fr)
GB (1) GB2595776B (fr)
IL (1) IL298542B2 (fr)
WO (2) WO2021116503A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PT3873883T (pt) 2019-11-07 2023-03-24 Small Pharma Ltd Método de síntese
KR20220137083A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP4188492A4 (fr) * 2020-07-29 2024-08-07 Gregory Ellis Système d'administration de substances de type ayahuasca
EP4200021A1 (fr) 2020-08-18 2023-06-28 Cybin IRL Limited Compositions de phénéthylamine thérapeutique et méthodes d'utilisation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
IL303288A (en) * 2020-12-01 2023-07-01 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
WO2022117640A1 (fr) 2020-12-01 2022-06-09 Small Pharma Ltd Formulations inhalables
EP4255422A4 (fr) 2020-12-03 2024-12-18 Mydecine Innovations Group Inc. Nouvelles compositions d'analogue de psilocine et leurs procédés de synthèse
MX2023013928A (es) 2021-05-25 2023-12-08 Atai Therapeutics Inc Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina.
JP2024522174A (ja) 2021-06-09 2024-06-11 アタイ セラピューティクス， インコーポレイテッド ジメチルトリプタミンの新規プロドラッグおよびコンジュゲート
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (fr) 2021-09-30 2023-04-05 Biomind Labs Inc Nanoparticules encapsulées et nanoparticules de diméthyltriptamines
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
JP2024540527A (ja) 2021-11-18 2024-10-31 サイビン ユーケー リミテッド 注射製剤及び吸入製剤
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
MX2024008691A (es) * 2022-01-14 2024-07-19 Cybin Irl Ltd Composiciones y metodos de triptamina.
EP4486448A1 (fr) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
WO2023186963A1 (fr) * 2022-03-31 2023-10-05 Cybin Irl Limited Combinaison d'oxyde nitreux et d'agonistes du récepteur 5-ht2a
CA3224835A1 (fr) 2022-05-10 2023-11-16 Mydecine Innovations Group Inc. Nouveaux composes de promedicaments de psilocine et leurs procedes de synthese
AU2023383549A1 (en) 2022-11-17 2025-06-05 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (fr) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2020245133A1 (fr) * 2019-06-03 2020-12-10 Small Pharma Ltd Compositions thérapeutiques comprenant des composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
WO2021089873A1 (fr) * 2019-11-07 2021-05-14 Small Pharma Ltd Procédé de synthèse

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (fr) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2020245133A1 (fr) * 2019-06-03 2020-12-10 Small Pharma Ltd Compositions thérapeutiques comprenant des composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
WO2021089873A1 (fr) * 2019-11-07 2021-05-14 Small Pharma Ltd Procédé de synthèse
WO2021089872A1 (fr) * 2019-11-07 2021-05-14 Small Pharma Ltd Composés

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARKER S A ET AL: "Comparison of the brain levels of N,N-dimethyltryptamine and @a,@a,@b,@b-tetradeutero-N,N-dimethyltryptamine following intraperitoneal injection", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 31, no. 15, 1 August 1982 (1982-08-01), pages 2513 - 2516, XP025521596, ISSN: 0006-2952, [retrieved on 19820801], DOI: 10.1016/0006-2952(82)90062-4 *
BEATON J M ET AL: "A comparison of the behavioral effects of proteo- and deutero-N, N-dimethyltryptamine", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 16, no. 5, 1 May 1982 (1982-05-01), pages 811 - 814, XP023806754, ISSN: 0091-3057, DOI: 10.1016/0091-3057(82)90240-4 *
MORRIS ET AL.: "Indolealkylamine metabolism: Synthesis of deuterated indolealkylamines as metabolic probes", JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 33, no. 6, 1993, pages 455 - 465, XP009522345, DOI: 10.1002/jlcr.2580330603 *

Also Published As

Publication number Publication date
EP4149460B8 (fr) 2025-01-08
IL298542B2 (en) 2025-02-01
GB2595776B (en) 2023-05-24
EP4149460C0 (fr) 2024-11-27
WO2021244831A1 (fr) 2021-12-09
EP4494703A2 (fr) 2025-01-22
JP7579888B2 (ja) 2024-11-08
EP4149460B1 (fr) 2024-11-27
IL298542A (en) 2023-01-01
IL298542B1 (en) 2024-10-01
EP3902541B1 (fr) 2022-09-14
WO2021116503A8 (fr) 2021-08-12
EP4149460A1 (fr) 2023-03-22
GB202106881D0 (en) 2021-06-30
EP3902541A2 (fr) 2021-11-03
EP4494703A3 (fr) 2025-04-02
WO2021116503A2 (fr) 2021-06-17
CN115996713A (zh) 2023-04-21
JP2023527575A (ja) 2023-06-29
AU2021284861A1 (en) 2023-01-05
GB2595776A (en) 2021-12-08
CA3118556A1 (fr) 2021-12-02

Similar Documents

Publication Publication Date Title
WO2021116503A3 (fr) Composés deutérés
PH12022551661A1 (en) Mek inhibitors and therapeutic uses thereof
EP4275753A3 (fr) Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
CA3142290C (fr) Compositions thérapeutiques comprenant des composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
MX2023006883A (es) Metodos para tratar el cancer de prostata.
SE0202134D0 (sv) Therapeutic agents
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
MX2021011647A (es) Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
JPWO2021244831A5 (fr)
RU2005123802A (ru) Производные адамантана, способы их получения и содержащие их фармацевтические композиции
MX2022014192A (es) Metodos para tratar el cancer de prostata.
RU2008100019A (ru) Способ лечения чрезмерной дневной сонливости (варианты)
MX2022014900A (es) Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
GB1116692A (en) A method for producing sydnonimine derivatives
MXPA05009660A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
FI2968346T3 (fi) Menetelmiä ja koostumuksia gamma-glutamyylisyklin muokkaamiseksi
ES2650139T3 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGluR 2/3
MX2023009285A (es) Compuestos novedosos.
CA2511242A1 (fr) Inhibiteurs de ccxckr2 d'expression tumorale humaine
TW202506673A (zh) 一種胺基吡啶類化合物、其製備方法、包含其藥物組合物及其應用
WO2005030143A3 (fr) Chelerythrine, analogues de celle-ci et leur utilisation pour traiter un trouble et d'autres troubles cognitifs
IL291570B1 (en) Pharmaceutical preparations
CA2613155A1 (fr) Regulateurs de recepteurs de peptide-1 de type glucagon, procedes de preparation et d'utilisation de ceux-ci
US20070197528A1 (en) Analogs of nitrobenzylthioinosine
WO2019032961A1 (fr) Conjugués trioxacarcine-anticorps et utilisations associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21720509

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021720509

Country of ref document: EP

Effective date: 20210729

ENP Entry into the national phase

Ref document number: 3179161

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022574099

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022024566

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227045704

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202217076779

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021204158

Country of ref document: AU

Date of ref document: 20210423

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022024566

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221130